Similar articles

• Re: Totect: a new agent for treating anthracycline extravasation.

  Ward MS. Ward MS. Clin J Oncol Nurs. 2007 Oct;11(5):613; author reply 613. doi: 10.1188/07.CJON.613. Clin J Oncol Nurs. 2007. PMID: 17962168 No abstract available.
• Totect: a new agent for treating anthracycline extravasation.

  Schulmeister L. Schulmeister L. Clin J Oncol Nurs. 2007 Jun;11(3):387-95. doi: 10.1188/07.CJON.387-395. Clin J Oncol Nurs. 2007. PMID: 17623623 Review.
• Dexrazoxane in anthracycline extravasation.

  Langer SW, Sehested M, Jensen PB, Buter J, Giaccone G. Langer SW, et al. J Clin Oncol. 2000 Aug;18(16):3064. J Clin Oncol. 2000. PMID: 10944144 No abstract available.
• Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy.

  Kane RC, McGuinn WD Jr, Dagher R, Justice R, Pazdur R. Kane RC, et al. Oncologist. 2008 Apr;13(4):445-50. doi: 10.1634/theoncologist.2007-0247. Oncologist. 2008. PMID: 18448560
• The use of dexrazoxane for the prevention of anthracycline extravasation injury.

  Hasinoff BB. Hasinoff BB. Expert Opin Investig Drugs. 2008 Feb;17(2):217-23. doi: 10.1517/13543784.17.2.217. Expert Opin Investig Drugs. 2008. PMID: 18230055 Review.